Table 3.

Comparison between Demographic Data and Thrombophilic Parameters in PVT Cases

Parameters		HCC (N=76) N(%)	Cirrhosis (N=24) No(%)	P- Value
Age (years)	Median (IQR)	60.0 (8)	33.0 (13)	0.32
	Min-max	43-65	68-35
Gender	Male	68 (89.5)	16 (66)	0.02*
	Female	8 (10.5)	8 (33.3)
JAK2 RS V617F	Positive	22 (28.9)	6 (25)	0.7
Organomegaly	Hepatomegaly	30 (39.5)	8 (33.3)	0.58
	Splenomegaly	66 (86.8)	16 (66.7)	0.03*
Smoking	Positive	13 (17.1)	4 (16.7)	0.94*
Diabetes mellitus	Positive	28 (36.8)	18 (75)	0.001
Protein C	Deficiency	20 (26.3)	8 (33.3)	0.5
Protein S	Deficiency	8 (10.5)	2 (8.3)	1.00*
ATIII	Deficiency	40 (52.6)	12 (50)	0.82
FVL	Mutation	10 (13.2)	2 (8.3)	0.72*
G20210A	Mutation	4 (5.3)	0 (0)	0.57*
MTHFR	Heterozygous	36 (47.4)	6 (25)	0.05
LA	Positive	8 (10.5)	2 (8.3)	1.00*
ACL (IgM)	Positive	6 (7.9)	2 (8.3)	1.00*
Ascites	Absent	18 (23.7)	12 (50)	0.01
	Present	58 (76.3)	12 (50)
History of DAAS	Receiving	42 (55.3)	10 (41.7)	0.27*
Child score	A	19 (26.3)	5 (33.3)	0.11
	B	22 (28.9)	9 (16.7)
	C	35 (46.1)	10 (50)

LA, lupus anticoagulant; ACL, anticardiolipin; DAAS, direct acting antiviral drugs; FVL, factor V Leiden; MTHFR,: methyl-tetrahydrofolate reductase; P>0.05 is non-significant; p <0.05: is significant; *Chi square test (x2) is used.